Heart failure therapy: what should clinicians believe?

Editorial

James C Fang. JAMA. 2012.

. 2012 Nov 28;308(20):2144-6.

doi: 10.1001/jama.2012.45418.

No abstract available

Comment on

Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.
Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH. Hernandez AF, et al. JAMA. 2012 Nov 28;308(20):2097-107. doi: 10.1001/jama.2012.14795. JAMA. 2012. PMID: 23188026
Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.
Lund LH, Benson L, Dahlström U, Edner M. Lund LH, et al. JAMA. 2012 Nov 28;308(20):2108-17. doi: 10.1001/jama.2012.14785. JAMA. 2012. PMID: 23188027